DISRUPT PAD III - International

Shockwave IVL Symposium at VIVA20:
Insights from the DISRUPT PAD III RCT in Severe Calcium

Key Findings

In the largest-ever randomized clinical trial of severely calcified peripheral lesions, IVL demonstrates superiority over PTA
IVL demonstrates a significant reduction in dissections and provisional stenting versus PTA
IVL achieves superior vessel preparation vs. PTA with lower pressure, fewer stents, less need for post-dilatation and fewer dissections
Disrupt PAD III randomized data confirm the consistent safety and effectiveness of IVL from previous studies in multiple vessel beds

306

SFA/Popliteal lesions
randomized to IVL or PTA

83%

Severe calcification by PARC by
an independent core-lab*

129mm

Average calcified length
by an independent core-lab*

*Data refer to IVL arm of randomized study

44%

Lower pressure to achieve better results with IVL versus PTA

75%

Reduction in provisional stent placement risk with IVL versus PTA

69%

Reduction in need for post-dilation versus PTA

79%

Reduction in Grade D Dissection with IVL versus PTA